ImmPACT Bio USA is developing logic-gated CAR T cell therapies that prevent antigen escape and rewire T cell responses to overcome the immunosuppressive tumor microenvironment in cancer. Their technology aims to enhance the specificity of T cell targeting, enabling effective treatment of solid tumors while sparing normal tissue.
Funding
Funding not disclosed
Founders
Product
Problem
Current CAR T-cell therapies face challenges such as antigen escape, where cancer cells evade treatment by downregulating the targeted antigen. The immunosuppressive tumor microenvironment also hinders T-cell activity, limiting the effectiveness of these therapies, particularly in solid tumors.
Solution
ImmPACT Bio is developing logic-gated CAR T-cell therapies designed to overcome these limitations. Their bispecific CAR T-cells address antigen escape by targeting multiple antigens simultaneously. In addition, ImmPACT Bio's technology rewires T-cell responses to counteract soluble factors within the tumor microenvironment, thereby enhancing T-cell infiltration and reducing T-cell exhaustion. Their iCAR technology further distinguishes cancer cells from normal cells, potentially enabling the effective treatment of solid tumors while sparing healthy tissue.
Target Audience
The primary target audience includes patients with cancer and autoimmune diseases who may benefit from advanced cell therapies, as well as clinicians and researchers in the fields of oncology and immunology.
Features
- Bispecific CAR T-cells designed to prevent antigen escape
- TGF-β CAR technology to rewire T-cell responses and overcome the immunosuppressive tumor microenvironment
- iCAR technology for specific killing of cancer cells while sparing normal tissue
- Logic-gate-based CAR T platforms to address key challenges in oncology
- Designed to enhance CAR T-cell infiltration, overcome T-cell exhaustion, and reduce regulatory T-cell activity